Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Lexicon Pharmaceuticals Inc. (LXRX) delivers innovative genomic-driven therapies for chronic diseases through its proprietary drug discovery platform. This page provides centralized access to official press releases, clinical trial updates, and strategic developments from the biopharmaceutical innovator.
Investors and industry observers will find timely updates on key initiatives including neuropathic pain treatment LX9211, diabetes therapies, and cardiovascular research. The resource aggregates regulatory milestones, partnership announcements, and scientific presentations while maintaining strict compliance with financial disclosure standards.
All content undergoes verification against primary sources to ensure accuracy. Users can monitor developments across Lexicon's pipeline – from preclinical research to commercialized products like INPEFA® – through curated news streams free of promotional language.
Bookmark this page for efficient tracking of LXRX's progress in advancing non-opioid pain management solutions and targeted metabolic therapies. Regular updates provide critical insights into the company's position within the evolving biopharmaceutical landscape.
Lexicon Pharmaceuticals (NASDAQ: LXRX) is set for a May 2023 PDUFA date for their NDA for sotagliflozin in heart failure treatment, confirmed during a recent FDA meeting. The company highlighted positive outcomes from their SOLOIST-WHF trial, showing a 50% reduction in readmission rates for heart failure post-discharge. For LX9211, the Phase 2 studies in diabetic peripheral neuropathic pain and postherpetic neuralgia showed promising results, though the latter's primary endpoint wasn't statistically significant. Financially, Q4 2022 recorded a net loss of $30.5 million but has $138.4 million in cash, a notable increase from $86.7 million in Q4 2021.
Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to release its fourth quarter financial results on March 2, 2023, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and provide a business update. Lexicon is known for its innovative medicines aimed at transforming patient lives through its Genome5000™ program, having identified over 100 therapeutic protein targets. They have advanced one drug to market and continue to develop candidates in areas such as neuropathic pain and diabetes. The company acknowledges potential risks related to capital requirements and regulatory approvals for its drug candidates.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the upcoming presentation of new analyses from the SOLOIST-WHF Phase 3 study of sotagliflozin at the American College of Cardiology’s 72nd Annual Scientific Session on March 4-6, 2023, in New Orleans. The presentations will include topics such as the time to clinical benefit and effects on symptoms and quality of life in patients with worsening heart failure. The SOLOIST-WHF study, involving 1,222 patients with type 2 diabetes, evaluated the cardiovascular efficacy of sotagliflozin compared to placebo and achieved its primary endpoint, demonstrating overall tolerability similar to placebo, as previously published in The New England Journal of Medicine.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in the 41st Annual JP Morgan Healthcare Conference from January 9-12, 2023. CEO Lonnel Coats will present on January 12, with an on-demand availability starting at 3:00 PM ET/12:00 PM PST. The presentation can be accessed via the Events section on Lexicon's website, and a recording will be available for two weeks after the event. Lexicon focuses on developing innovative medicines through its Genome5000™ program, targeting significant therapeutic proteins.
Lexicon Pharmaceuticals announced topline results from the RELIEF-PHN-1 Phase 2 study of LX9211 for postherpetic neuralgia, demonstrating a reduction of 2.42 in average daily pain score (ADPS) at week 6 compared to a 1.62 reduction in the placebo group. Though not statistically significant at the primary endpoint (p=0.12), a consistent effect was noted across the dosing period (p=0.03). The adverse event profile was similar to prior studies, with dizziness being the most common issue. A full analysis will be shared at a medical conference.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will participate in two investor conferences on November 29 and December 1, 2022. The conferences include the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference. Key executives, including CEO Lonnel Coats and CFO Jeffrey Wade, will engage in discussions at these events. Webcasts of the discussions will be accessible on Lexicon's website, with recordings available for two weeks post-event. Lexicon focuses on developing innovative medicines targeting various diseases.
Lexicon Pharmaceuticals (LXRX) announced successful results from the RELIEF-DPN-1 trial of its investigational drug LX9211, aimed at treating diabetic peripheral neuropathic pain. The trial achieved its primary endpoint, showing a statistically significant reduction in average daily pain score (ADPS) at week 6. Significant benefits were also noted in reducing burning pain and sleep interference. No withdrawal symptoms or rebound pain were observed post-treatment. The company plans to advance LX9211 to phase 3 development in 2023, further supporting its potential as a treatment for neuropathic pain.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its participation in the 13th Annual Jefferies London Healthcare Conference from November 15-17, 2022. Jeff Wade, the company's president and CFO, is set to present, with the on-demand presentation available starting 7:55 am ET on November 16. The webcast will be accessible in the Events section of Lexicon's website, with a recording available for two weeks post-event.
Lexicon focuses on pioneering medicines for various diseases through its Genome5000™ program.
Lexicon Pharmaceuticals (LXRX) announced its financial results for Q3 2022, reporting a net loss of $23.4 million, or $0.13 per share. The FDA's review of their NDA for sotagliflozin for heart failure is on track for a PDUFA date in May 2023. The company presented new data from the SOLOIST-WHF trial highlighting sotagliflozin's benefits in reducing cardiovascular mortality. Additionally, final results from the RELIEF-DPN-1 study of LX9211 in painful diabetic neuropathy will be presented at an upcoming summit. As of September 30, 2022, Lexicon had $136.2 million in cash and investments.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced the final results from its Phase 2 RELIEF-DPN-1 trial for LX9211, a selective AAK1 inhibitor, aimed at treating diabetic peripheral neuropathic pain. The results will be presented on November 14, 2022, showing a significant reduction in pain scores compared to placebo. The study enrolled 319 patients across 45 clinical sites, demonstrating potential efficacy and safety. The company also plans to release results from another related study by year-end 2022.
FAQ
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
